Analysis of patients with rheumatoid arthritis (RA) of less than 3 years’ duration who met criteria for inclusion in the early RA (ERA) clinical trial according to therapies taken
| Prior methotrexate status | No. of patients | No. (%) who met inclusion criteria for ERA clinical trial* |
|---|---|---|
| * Inclusion criteria: 12 or more tender joints and 10 or more swollen joints; positive rheumatoid factor or radiographic erosions; morning stiffness of 45 minutes or more or ESR of 28 mm/hr or more. | ||
| Source: Sokka et al. Arthritis Rheum 2003;48:313–18.31 | ||
| No prior methotrexate: first visit | 19 | 8 (42%) |
| No prior methotrexate: not first visit | 17 | 3 (18%) |
| All no prior methotrexate | 36 | 11 (31%) |
| Prior methotrexate, leflunomide, etanercept or infliximab | 196 | 26 (13%) |
| Total—all patients | 232 | 37 (16%) |